The Impact of Cannabidiol on Human Brain Function : A Systematic Review Albert Batalla, Julian Bos, Amber Postma and Matthijs G. Bossong Frontiers in Pharmacology, January 2021 | Volume 11 | Article 618184, 1-15. doi : 10.3389/fphar.2020.618184 Background : Accumulating evidence suggests that the non-intoxicating cannabinoid compound cannabidiol (CBD) may have antipsychotic and anxiolytic properties, and thus may be a promising new agent in the treatment of psychotic and anxiety disorders. However, the neurobiological substrates underlying the potential therapeutic effects of CBD are still unclear. The aim of this systematic review is to provide a detailed and up-todate systematic literature overview of neuroimaging studies [...]
Lire la suiteBirth Outcomes of Neonates Exposed to Marijuana in Utero. A Systematic Review and Meta-analysis Greg Marchand, MD; Ahmed Taher Masoud, MD; Malini Govindan, MD; KellyWare, MS; Alexa King, BS; Stacy Ruther, BS; Giovanna Brazil, BS; Hollie Ulibarri, BS; Julia Parise, BS; Amanda Arroyo, BS; Catherine Coriell, BS; Sydnee Goetz, BS; Amitis Karrys, BS; Katelyn Sainz, MD JAMA Network Open, 2022, 5, (1), e2145653, 1-13. doi : 10.1001/jamanetworkopen.2021.45653 Abstract IMPORTANCE While some studies have found an association between marijuana use and adverse neonatal outcomes, results have not been consistent across all trials. OBJECTIVE To assess available data on neonatal outcomes in marijuana-exposed pregnancies. DATA SOURCES PubMed, Medline, ClinicalTrials.gov, [...]
Lire la suiteEDITORIAL : Cannabinoids in psychiatry : they are here to stay Julia Jiyeon Woo, Emma van Reekum, Sagnik Bhattacharyya and Zainab Samaan The British Journal of Psychiatry, 2022, 1-3. doi : 10.1192/bjp.2021.216 Summary Cannabinoids are commonly perceived by the public as safe and effective for improving mental health, despite limited evidence to support their use. We discuss reasons why cannabinoids may be particularly compelling for our patients and provide strategies for how psychiatrists can counsel and educate patients on the evidence regarding cannabinoids. Keywords : Cannabis; drug interactions and side-effects; drugs of dependence disorders; marijuana; education and training. Vignette A young man sits in his psychiatrist’s office. After [...]
Lire la suiteCannabinoids Block Cellular Entry of SARS-CoV‑2 and the Emerging Variants Richard B. van Breemen, Ruth N. Muchiri, Timothy A. Bates, Jules B. Weinstein, Hans C. Leier, Scotland Farley, and Fikadu G. Tafesse Journal of Natural Products, 2022, 85, 176−184. Doi : 10.1021/acs.jnatprod.1c00946 ABSTRACT : As a complement to vaccines, small-molecule therapeutic agents are needed to treat or prevent infections by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its variants, which cause COVID-19. Affinity selection−mass spectrometry was used for the discovery of botanical ligands to the SARS-CoV-2 spike protein. Cannabinoid acids from hemp (Cannabis sativa) were found to be allosteric as well as orthosteric ligands [...]
Lire la suiteBibliographie : Cannabis et Cannabinoides en Psychiatrie Docteur Christian Sueur, GRECC, janvier 2022. (5e version, janvier 2022....) 1 - Généralités : 1 - 11 2 -Cannabinoïdes et anxiété : 12 3 - Cannabidiol anxiolytique : 13 - 15 4 - Cannabidiol antipsychotique : 16 - 21 5 - Cannabinoïdes et dépression : 22 - 28 6 - Cannabidiol antidépresseur : 28 7 - Cannabinoïdes et Sommeil : 29 - 30 8 - Cannabinoïdes et addiction / Substance Use Disorders : 31 - 33 9 - Cannabinoïdes et addiction au Cannabis : 34 - 43 10 - Cannabinoïdes et addictions (cocaine, opiacés, amphétamines, alcool, tabac) : 44 - 57 11 - Cannabinoides et syndrome de Gilles [...]
Lire la suiteEarly Consumption of Cannabinoids : From Adult Neurogenesis to Behavior Citlalli Netzahualcoyotzi, Luis Miguel Rodríguez-Serrano, María Elena Chávez-Hernández and Mario Humberto Buenrostro-Jáuregui International Journal of Molecular Sciences, 2021, 22, 7450. doi : 10.3390/ijms22147450 Abstract The endocannabinoid system (ECS) is a crucial modulatory system in which interest has been increasing, particularly regarding the regulation of behavior and neuroplasticity. The adolescent–young adulthood phase of development comprises a critical period in the maturation of the nervous system and the ECS. Neurogenesis occurs in discrete regions of the adult brain, and this process is linked to the modulation of some behaviors. Since marijuana (cannabis) is the most consumed illegal [...]
Lire la suiteCannabinoids and the endocannabinoid system in reward processing and addiction: from mechanisms to interventions Rainer Spanagel, PhD Dialogues in Clinical Neuroscience, 2020, 22, (3), 241-250. doi : 10.31887/DCNS.2020.22.3/rspanagel The last decades have seen a major gain in understanding the action of cannabinoids and the endocannabinoid system in reward processing and the development of addictive behavior. Cannabis-derived psychoactive compounds such as Δ9-tetrahydrocannabinol and synthetic cannabinoids directly interact with the reward system and thereby have addictive properties. Cannabinoids induce their reinforcing properties by an increase in tonic dopamine levels through a cannabinoid type 1 (CB1) receptor–dependent mechanism within the ventral tegmental area. Cues that are conditioned [...]
Lire la suiteThe (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders: Molecular Mechanisms and Targets Rosa Maria Vitale, Fabio Arturo Iannotti and Pietro Amodeo International journal of Molecular Sciences, 2021, 22, 4876, 1-20. Doi : 10.3390/ijms22094876 Abstract : Cannabidiol (CBD), the major nonpsychoactive Cannabis constituent, has been proposed for the treatment of a wide panel of neurological and neuropsychiatric disorders, including anxiety, schizophrenia, epilepsy and drug addiction due to the ability of its versatile scaffold to interact with diverse molecular targets that are not restricted to the endocannabinoid system. Albeit the molecular mechanisms responsible for the therapeutic effects of CBD have yet to be fully elucidated, many [...]
Lire la suiteCannabidiol as a Treatment for Mood Disorders : A Systematic Review Le cannabidiol comme traitement des troubles de l’humeur : une revue systématique Jairo Vinicius Pinto, MD, Gayatri Saraf, MD, Christian Frysch, MD, Daniel Vigo, MD, DrPH, Kamyar Keramatian, MD, MSc, FRCPC, Trisha Chakrabarty, MD, Raymond W. Lam, MD, Marcia Kauer-Sant’Anna, MD, PhD, and Lakshmi N. Yatham, MBBS, FRCPC The Canadian Journal of Psychiatry /La Revue Canadienne de Psychiatrie, 2020, Vol. 65, (4), 213-227. Doi : 10.1177/0706743719895195 Abstract Objective : To review the current evidence for efficacy of cannabidiol in the treatment of mood disorders. Methods : We systematically searched PubMed, Embase, Web of Science, PsychInfo, Scielo, [...]
Lire la suiteCannabidiol as a treatment for craving and relapse inindividuals with cocaine use disorder: a randomized placebo-controlled trial Violaine Mongeau-Pérusse, Suzanne Brissette, Julie Bruneau, Patricia Conrod, Simon Dubreucq, Guillaume Gazil, EmmanuelStip & DidierJutras-Aswad Addiction, 2021, 116, (9), 1-12. Doi : 10.1111/add.15417 ABSTRACT Background and Aims : Cocaine use disorder (CUD) is a significant public health concern for which no efficacious phar-macologicalinterventionsare available. Cannabidiol (CBD) has attracted considerable interest as a promisingtreatmentforaddiction. This study tested CBD efficacy for reducing craving and preventing relapse in people with CUD.DesignSingle-site double-blind randomized controlled superiority trial comparing CBD with placebo. Setting and Participants : Centre Hospitalier de l’Université de Montréal, Canada. Seventy-eight [...]
Lire la suite